What Determines Breast Cancer Treatment? (2026 Update)

There is no single, one-size-fits-all answer for breast cancer treatment. The sequence of surgery and choice of medication depend on the subtype—determined by hormone receptor (ER, PR), HER2, and Ki-67 test results—as well as the stage of disease.

Key Takeaways

• Breast cancer subtype is determined through ER, PR, HER2, and Ki-67 testing, and this subtype dictates the sequence of surgery, chemotherapy, targeted therapy, and hormone therapy.
• Korea's 5-year relative survival rate for breast cancer is 94.7% (National Cancer Registration Statistics 2019–2023, National Cancer Center Korea). This reflects nationwide statistics, not the performance of any individual hospital.
• According to SEER data in the United States, the 5-year relative survival rate for female breast cancer is 91.9% (2016–2022). Neither figure predicts an individual patient's outcome.
• For HER2-positive or triple-negative breast cancer, the standard approach is typically to begin with chemotherapy (combined with targeted therapy when appropriate) before surgery.
• For stage 4 (metastatic) breast cancer, the goal shifts from cure to long-term, comfortable disease control—achieved through combinations such as hormone therapy plus CDK4/6 inhibitors, anti-HER2 therapy, or immunotherapy, depending on subtype.

What determines breast cancer treatment?

The first factor in determining treatment is subtype. Biopsy results reveal estrogen receptor (ER) status, progesterone receptor (PR) status, HER2 status, and Ki-67 (a marker of cell proliferation speed)—together, these four markers form the starting point for the treatment plan. Even at the same stage, a different subtype can completely change both the order of surgery and the medications used.

How does treatment differ by stage?

For stages 0 through 2, surgery is the central approach. For stage 3 or higher, or for HER2-positive and triple-negative cases, chemotherapy before surgery is often the standard. At stage 0 (carcinoma in situ), surgery is performed along with radiation therapy if breast-conserving surgery is chosen. At stages 1–2, breast-conserving surgery or total mastectomy is combined with sentinel lymph node biopsy. At stage 3, the typical approach is to shrink the tumor with chemotherapy first, then perform surgery. At stage 4, the goal is long-term, comfortable disease management using combinations tailored to subtype—hormone therapy plus CDK4/6 inhibitors, anti-HER2 targeted therapy, antibody-drug conjugates, or immunotherapy. If hormone receptors are positive, hormone therapy continues for 5 to 10 years after surgery.

Why is chemotherapy sometimes given before surgery?

For HER2-positive or triple-negative breast cancer, giving chemotherapy first allows doctors to see in real time whether the drug is actually working, and shrinking the tumor beforehand increases the chances of breast-conserving surgery. The extent of any residual tumor after surgery can also guide the choice of subsequent medication. This approach is commonly chosen for stage 3 disease or in cases where pre-surgical treatment is expected to be advantageous.

FAQ — Which hospital's results do these survival rates represent?

These figures are not the results of any specific hospital. They come from Korea's National Cancer Registration Statistics (2019–2023, National Cancer Center Korea), representing the country as a whole. Under Korean medical law, individual hospitals are not permitted to use their own outcome statistics in advertising, and actual results can vary significantly depending on a patient's subtype, stage, and overall health condition.

FAQ — If I have a total mastectomy, can breast reconstruction be done the same day?

In many cases, immediate reconstruction can be performed at the same time as the mastectomy. The choice between implant-based reconstruction and autologous tissue reconstruction depends on body type, planned radiation therapy, and personal preference regarding recovery time. If radiation therapy is planned, the timing of reconstruction may be adjusted accordingly. The final decision should be made in consultation with your medical team.

Sources and Notes

This article was written based on National Cancer Registration Statistics 2019–2023 (National Cancer Center Korea, Central Cancer Registry), SEER data (2016–2022), and NCCN patient guidelines. This content is intended for general medical information purposes only. Actual diagnosis, treatment methods, and outcomes may vary depending on individual circumstances. Please consult your medical team for an accurate diagnosis and treatment plan.